Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sarepta Therapeutics, Inc.

< Previous 1 2 Next >
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the UBS Biopharma Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.